WO2008113916A3 - Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w - Google Patents

Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w Download PDF

Info

Publication number
WO2008113916A3
WO2008113916A3 PCT/FR2008/000166 FR2008000166W WO2008113916A3 WO 2008113916 A3 WO2008113916 A3 WO 2008113916A3 FR 2008000166 W FR2008000166 W FR 2008000166W WO 2008113916 A3 WO2008113916 A3 WO 2008113916A3
Authority
WO
WIPO (PCT)
Prior art keywords
directed against
herv
pharmaceutical composition
envelope
composition containing
Prior art date
Application number
PCT/FR2008/000166
Other languages
English (en)
Other versions
WO2008113916A9 (fr
WO2008113916A2 (fr
Inventor
Herve Perron
Original Assignee
Geneuro Sa
Herve Perron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneuro Sa, Herve Perron filed Critical Geneuro Sa
Priority to US12/449,327 priority Critical patent/US20100074894A1/en
Priority to EP08761866A priority patent/EP2117594A2/fr
Publication of WO2008113916A2 publication Critical patent/WO2008113916A2/fr
Publication of WO2008113916A3 publication Critical patent/WO2008113916A3/fr
Publication of WO2008113916A9 publication Critical patent/WO2008113916A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant, à titre de principe actif, au moins un anticorps dirigé contre la protéine d'enveloppe de HERV- W, à l'exclusion de tout anticorps dirigé spécifiquement contre le site de liaison entre ladite protéine env et le récepteur hASCTl ou hASCT2.
PCT/FR2008/000166 2007-02-09 2008-02-11 Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w WO2008113916A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/449,327 US20100074894A1 (en) 2007-02-09 2008-02-11 Pharmaceutical composition containing antibodies directed against the herv-w envelope
EP08761866A EP2117594A2 (fr) 2007-02-09 2008-02-11 Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0700952 2007-02-09
FR0700952A FR2912314B1 (fr) 2007-02-09 2007-02-09 Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.

Publications (3)

Publication Number Publication Date
WO2008113916A2 WO2008113916A2 (fr) 2008-09-25
WO2008113916A3 true WO2008113916A3 (fr) 2008-11-27
WO2008113916A9 WO2008113916A9 (fr) 2009-01-22

Family

ID=38457775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/000166 WO2008113916A2 (fr) 2007-02-09 2008-02-11 Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w

Country Status (4)

Country Link
US (1) US20100074894A1 (fr)
EP (1) EP2117594A2 (fr)
FR (1) FR2912314B1 (fr)
WO (1) WO2008113916A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010014319A (es) 2008-07-08 2011-05-19 Geneuro Sa Uso terapeutico de ligando especifico en enfermedades asociadas con msrv.
US10370417B2 (en) 2011-03-01 2019-08-06 Rutgers, The State University Of New Jersey Methods for the diagnosis of cancer through detection of human endogenous retrovirus WL (HERV-WL) envelope expression
WO2012118974A2 (fr) * 2011-03-01 2012-09-07 University Of Medicine And Dentistry Of New Jersey Détection d'expression de rétrovirus endogène humain dans des cellules cancéreuses et des cellules saines
EP2949342A1 (fr) * 2014-05-28 2015-12-02 Geneuro SA Médicaments antirétroviraux ciblant un rétrovirus endogène humain
CN108472394A (zh) * 2015-10-05 2018-08-31 梅塔福拉生物系统公司 用于检测、诊断和治疗胰腺癌的受体结合结构域配体
WO2017083451A1 (fr) 2015-11-10 2017-05-18 Medimmune, Llc Molécules de liaison spécifiques d'asct2 et leurs utilisations
EP3351265A1 (fr) * 2017-01-20 2018-07-25 Geneuro SA Anticorp du herv-k enveloppe et ses utilisations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001031021A1 (fr) * 1999-10-28 2001-05-03 Universite De Geneve Superantigene lie a la sclerose en plaques
WO2005080437A1 (fr) * 2004-01-23 2005-09-01 Biomerieux Composition pour le traitement d'une pathologie associee a la msrv/herv-w

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001031021A1 (fr) * 1999-10-28 2001-05-03 Universite De Geneve Superantigene lie a la sclerose en plaques
WO2005080437A1 (fr) * 2004-01-23 2005-09-01 Biomerieux Composition pour le traitement d'une pathologie associee a la msrv/herv-w

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLOND J-L ET AL: "ENVELOPE GLYCOPROTEIN OF THE HUMAN ENDOGENOUS RETROVIRUS HERV-W IS EXPRESSED IN THE HUMAN PLACENTA AND FUSES CELLS EXPRESSING THE TYPED MAMMALIAN RETROVIRUS RECEPTOR", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 7, April 2000 (2000-04-01), pages 3321 - 3329, XP000946327, ISSN: 0022-538X *
CHEYNET V ET AL: "Synthesis, assembly, and processing of the Env ERVWE1/syncytin human endogenous retroviral envelope", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 79, no. 9, May 2005 (2005-05-01), pages 5585 - 5593, XP002402067, ISSN: 0022-538X *
CHEYNET VALÉRIE ET AL: "Identification of the hASCT2-binding domain of the Env ERVWE1/syncytin-1 fusogenic glycoprotein.", RETROVIROLOGY 2006, vol. 3, 2006, pages 41, XP002450965, ISSN: 1742-4690 *
LAVILLETTE DIMITRI ET AL: "The envelope glycoprotein of human endogenous retrovirus type W uses a divergent family of amino acid transporters/cell surface receptors", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 76, no. 13, July 2002 (2002-07-01), pages 6442 - 6452, XP002289561, ISSN: 0022-538X *
MI SHA ET AL: "Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis", NATURE, NATURE PUBLISHING GROUP, LONDON, US, vol. 403, no. 6771, 17 February 2000 (2000-02-17), pages 785 - 789, XP002147935, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
FR2912314B1 (fr) 2012-08-03
US20100074894A1 (en) 2010-03-25
EP2117594A2 (fr) 2009-11-18
WO2008113916A9 (fr) 2009-01-22
FR2912314A1 (fr) 2008-08-15
WO2008113916A2 (fr) 2008-09-25

Similar Documents

Publication Publication Date Title
WO2007106744A3 (fr) Anticorps anti-5t4 et leurs utilisations
WO2009070243A3 (fr) Agents et épitopes de liaison à wise
WO2009034119A8 (fr) Dérivés améliorés de l'amyline
WO2008079995A3 (fr) Conjugué comprenant un peptide natriurétique et une région constante d'un anticorps
WO2008060705A3 (fr) Anticorps anti-dll4 et leurs procédés d'utilisation
WO2008082669A3 (fr) Conjugués polymère-facteur viii et facteur von willebrand comprenant une liaison dégradable
WO2008113916A9 (fr) Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w
WO2007130697A3 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
IL199216A (en) Monoclonal Antibodies Against 3angptl, Pharmaceuticals Containing Them and Their Uses
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
WO2007120334A8 (fr) Méthodes et compositions de ciblage de la polyubiquitine
WO2007133290A3 (fr) Anticorps anti-ox40l et méthodes correspondantes
WO2010145792A8 (fr) Protéines bispécifiques se liant à un antigène
WO2008121767A3 (fr) Polypeptides cousus
WO2006138343A3 (fr) Compositions comprenant des variants de proteine associee au recepteur (rap) specifiques a lrp2, et utilisations correspondantes
WO2008157356A3 (fr) Formulations d'anticorps
WO2006083936A3 (fr) Anticorps anti-ephb2 et methodes d'utilisation associees
WO2007075525A3 (fr) Combinaison de composes organiques
WO2009128963A3 (fr) Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
IL211010A (en) Antibody, antibody hybridoma, antibody-containing conjugate, antibody-containing drug and / or conjugate and their uses
NO20061346L (no) Peptider og forbindelser som binder til thrombopoietin-reseptorer
WO2007127506A8 (fr) Anticorps anti-ephrinb2 et procédés les utilisant
IL200388A (en) Antibody, antibody hybridoma, antibody-containing conjugate, antibody-containing drug and / or conjugate and their uses
WO2008049990A3 (fr) Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
WO2007149932A3 (fr) Procédés et compositions pour cibler l'hepsine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08761866

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008761866

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12449327

Country of ref document: US